幼年粒单核细胞白血病
医学
PTPN11型
神经母细胞瘤RAS病毒癌基因同源物
克拉斯
造血干细胞移植
肿瘤科
移植
靶向治疗
骨髓增生异常综合症
骨髓增生性肿瘤
白血病
内科学
癌症研究
免疫学
干细胞
骨髓纤维化
造血
癌症
骨髓
生物
结直肠癌
遗传学
作者
Nele De Vos,Mattias Hofmans,Tim Lammens,Bram De Wilde,Nadine Van Roy,Barbara De Moerloose
摘要
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive clonal neoplasm of early childhood, classified as an overlap myeloproliferative/myelodysplastic neoplasm by the World Health Organization. In 90% of the patients with JMML, typical initiating mutations in the canonical Ras pathway genes NF1, PTPN11, NRAS, KRAS, and CBL can be identified. Hematopoietic stem cell transplantation (HSCT) currently is the established standard of care in most patients, although long-term survival is still only 50-60%. Given the limited therapeutic options and the important morbidity and mortality associated with HSCT, new therapeutic approaches are urgently needed. Hyperactivation of the Ras pathway as disease mechanism in JMML lends itself to the use of targeted therapy. Targeted therapy could play an important role in the future treatment of patients with JMML. This review presents a comprehensive overview of targeted therapies already developed and evaluated in vitro and in vivo in patients with JMML.
科研通智能强力驱动
Strongly Powered by AbleSci AI